Bristol-Myers Squibb Company (BRM BE) stock market data APIs
€39.0828
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
Bristol-Myers Squibb Company Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for BRM.BE.
Prev. Close
39.0828
Open
39.0828
High
39.0828
Low
39.0828
52 wk Range
37.945-56.7783
Market Cap
110 771 M
Dividends (Yield)
0.0157
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bristol-Myers Squibb Company data using free add-ons & libraries
Get Bristol-Myers Squibb Company Fundamental Data
Bristol-Myers Squibb Company Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bristol-Myers Squibb Company News
New
Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test
Biocartis NV PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnost...
![Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma](/build/assets/fallback7-edDikJRC.jpg)
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Perspective Therapeutics, Inc. First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab [212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWS...
How Bad Is This Sector’s Health Scare?
Do not buy healthcare fund if you are allergic to any of its ingredients. After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year. F...
BioNTech (BNTX) Faces Legal Challenges Over mRNA Patent
BioNTech has been under scrutiny due to significant legal challenges, including a recent claim construction ruling in a patent lawsuit involving its COVID-19 mRNA vaccine technology. At the same time,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
